Bioorthogonal chemistry for prodrug activation in vivo
Prodrugs have emerged as a major strategy for addressing clinical challenges by improving
drug pharmacokinetics, reducing toxicity, and enhancing treatment efficacy. The emergence …
drug pharmacokinetics, reducing toxicity, and enhancing treatment efficacy. The emergence …
Bioorthogonal chemistry for prodrug activation in vivo
Q Fu, S Shen, P Sun, Z Gu, Y Bai… - Chemical Society … - pubmed.ncbi.nlm.nih.gov
Prodrugs have emerged as a major strategy for addressing clinical challenges by improving
drug pharmacokinetics, reducing toxicity, and enhancing treatment efficacy. The emergence …
drug pharmacokinetics, reducing toxicity, and enhancing treatment efficacy. The emergence …
Bioorthogonal chemistry for prodrug activation in vivo.
Q Fu, S Shen, P Sun, Z Gu, Y Bai, X Wang… - Chemical Society …, 2023 - europepmc.org
Prodrugs have emerged as a major strategy for addressing clinical challenges by improving
drug pharmacokinetics, reducing toxicity, and enhancing treatment efficacy. The emergence …
drug pharmacokinetics, reducing toxicity, and enhancing treatment efficacy. The emergence …